The Latest Breakthrough in Gene Therapy Aggregate Analysis
Phenomenex Inc., a global leader in the research and manufacture of advanced technologies for the separation sciences, proudly announces its newest Size Exclusion Chromatography (SEC) product, Biozen dSEC-7, for the analysis of AAVs (adeno-associated viral vectors). In the emerging field of gene therapy, modified DNA promises immense potential for healthcare transformation. Biozen dSEC-7 offers a new solution for aggregate analysis, joining the existing Biozen portfolio of biological workflow products that are targeted for the analysis of monoclonal antibodies, biosimilars, and other biomolecules.
“The introduction of Biozen dSEC-7 marks a leap forward in our commitment to supporting researchers advancing gene therapy,” says Dr. Kaveh Kahen, President of Phenomenex. “This innovative tool empowers scientists to study AAVs with unprecedented efficiency, bringing drug discovery laboratories closer to advancing the availability of gene therapies for treating diseases and improving healthcare outcomes.”
The proprietary dSEC-7 particle technology and surface chemistry for characterizing AAVs result in consistent, reproducible results and facilitate a faster and more efficient mode of analysis compared to traditional methods. The newly designed particle allows for reduction in run times and sample consumption, ensuring that laboratories can achieve higher quality data for AAVs using these advancements in chromatographic methods.
Phenomenex reaffirms its commitment to leading chromatography solutions, empowering researchers and scientists with tools tailored to advance the frontiers of gene therapy and reshape the landscape of healthcare.
About Phenomenex
Phenomenex is a global technology leader committed to developing novel analytical chemistry solutions that solve the separation and purification challenges of researchers in academic, pharmaceutical, biotech, environmental, clinical research, government, and industrial laboratories. From drug discovery and pharmaceutical development to food safety and environmental analysis, Phenomenex chromatography solutions accelerate science and help researchers improve human health and well-being. Phenomenex is an operating company within the Life Sciences group of Danaher Corporation.
https://www.prnewswire.com/news-releases/phenomenex-introduces-biozen-dsec-7-a-new-way-to-study-aavs-with-unprecedented-speed-and-efficiency-302078925.html
Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Exploring Tau Protein’s Role in Glaucoma: New Insights and Therapeutic Potential
Glaucoma, a chronic neurodegenerative disorder, leads to irreversible vision loss by damaging retinal ganglion cells (RGCs) and the optic nerve, often associated with increased intraocular pressure (IOP). Despite the benefits of IOP-lowering treatments, the underlying...
FDA-mandated CAR-T monitoring period could be halved, say researchers
In patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCL), the two hallmark post-chimeric antigen receptor (CAR)-T therapy toxicities are extremely rare after two weeks, supporting a shorter, more flexible toxicity monitoring period, according to a study...
Ancestral CRISPR-Cas13 Ribonucleases Discovered: Implications for Genome Editing
In a pioneering study published in *Science*, a team of researchers led by Peter H. Yoon and Jennifer A. Doudna from the University of California, Berkeley, has made a remarkable discovery in the realm of CRISPR technology. The team has identified an ancestral clade...
KBI Biopharma Expands Manufacturing Contract with Global Pharmaceutical Company
KBI Biopharma Inc., a JSR Life Sciences company and global cGMP contract development and manufacturing organization (CDMO), has extended and expanded its manufacturing contract with a leading global pharmaceutical company. Originally initiated in 2020, the renewed...
Related Services
Plasmids GMP Services
AAV GMP Services
